Targeting HER3 in Patients with Advanced NSCLC

home / insights / targeting-her3-in-patients-with-advanced-nsclc

Ticiana Leal, MD, and Sandip P. Patel, MD, discuss the treatment landscape for patients with advanced non–small cell lung cancer and the emerging role of targeting HER3.

Sandip P. Patel, MD, and Ticiana Leal, MD, experts on lung cancer

EP. 1: Current Treatment Landscape for EGFR-Mutated NSCLC

Ticiana A. Leal, MD;Sandip P. Patel, MD
October 12th 2023

Medical oncologists specializing in lung cancer give an overview of the current treatment landscape for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Sandip P. Patel, MD, an expert on lung cancer

EP. 2: Treatment Options for EGFR-Mutated NSCLC Following Progression

Ticiana A. Leal, MD;Sandip P. Patel, MD
October 12th 2023

Sandip P. Patel, MD, discusses treatment options available for patients with EGFR-mutated NSCLC who progress on EGFR TKIs and platinum-based chemotherapy.

Ticiana Leal, MD, an expert on lung cancer

EP. 3: EGFR-Mutated NSCLC: Treatment Options Following Progression on Osimertinib

Ticiana A. Leal, MD;Sandip P. Patel, MD
October 19th 2023

Ticiana Leal, MD, gives a comprehensive overview of treatment options for patients with EGFR-mutated NSCLC who progress on osimertinib therapy.

Sandip P. Patel, MD, and Ticiana Leal, MD, experts on lung cancer

EP. 4: Treatments and Unmet Needs for EGFR-Mutated NSCLC

Ticiana A. Leal, MD;Sandip P. Patel, MD
October 19th 2023

Expert perspectives on unmet needs and therapies available for patients with EGFR-mutated non–small cell lung cancer.

Sandip P. Patel, MD, an expert on lung cancer

EP. 5: The Role of HER3 in Non–Small Cell Lung Cancer

Ticiana A. Leal, MD;Sandip P. Patel, MD
October 26th 2023

A medical oncologist discusses the role of HER3 in the treatment of non–small cell lung cancer and provides an overview of the HERTHENA-Lung01 clinical trial.

Sandip P. Patel, MD, and Ticiana Leal, MD, experts on lung cancer

EP. 6: HERTHENA-Lung01: Patritumab Deruxtecan in Advanced EGFR-Mutated NSCLC

Ticiana A. Leal, MD;Sandip P. Patel, MD
October 26th 2023

Experts on lung cancer review key data from the HERTHENA-Lung01 study investigating patritumab deruxtecan (HER3-DXd) in patients with advanced EGFR-mutated NSCLC.

Sandip P. Patel, MD, and Ticiana Leal, MD, experts on lung cancer

EP. 7: NSCLC: Safety Outcomes from HERTHENA-Lung01

Ticiana A. Leal, MD;Sandip P. Patel, MD
November 2nd 2023

Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.

Sandip P. Patel, MD, and Ticiana Leal, MD, experts on lung cancer

EP. 8: Role of HER3-DXd in Advanced NSCLC Treatment Landscape

Ticiana A. Leal, MD;Sandip P. Patel, MD
November 2nd 2023

Clinical insights on where patritumab deruxtecan might fit in the treatment paradigm for patients with advanced non–small cell lung cancer.

Sandip P. Patel, MD, and Ticiana Leal, MD, experts on lung cancer

EP. 9: Ongoing Research on HER3-DXd in NSCLC

Ticiana A. Leal, MD;Sandip P. Patel, MD
November 9th 2023

Ticiana Leal, MD, and Sandip P. Patel, MD, discuss clinical trials evaluating the use of patritumab deruxtecan in patients with non–small cell lung cancer and remaining unmet needs.